跳至主要内容
临床试验/NCT06333457
NCT06333457
已完成
不适用

Presence and Relapse Rates in Patients With Alcohol Use Disorder Using Virtual Reality

Charite University, Berlin, Germany1 个研究点 分布在 1 个国家目标入组 60 人2024年4月1日

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Alcohol Dependence
发起方
Charite University, Berlin, Germany
入组人数
60
试验地点
1
主要终点
Craving
状态
已完成
最后更新
3个月前

概览

简要总结

Investigation of the influence of the sense of presence during a Virtual Reality Cue-Exposure Therapy (VR-CET) with alcohol-associated cues on craving and relapse rates.

Study group: abstinent patients (at least 18 years old) with a diagnosed alcohol dependence after completed inpatient withdrawal treatment in the the last 3 months.

Primary hypothesis: the experience of presence during a virtual presentation of alcohol in alcohol-dependent patients is associated with levels of craving for alcohol during VR-CET.

注册库
clinicaltrials.gov
开始日期
2024年4月1日
结束日期
2025年3月30日
最后更新
3个月前
研究类型
Observational
性别
All

研究者

责任方
Principal Investigator
主要研究者

Alva Lütt

Dr. med.

Charite University, Berlin, Germany

入排标准

入选标准

  • age: 18-65 years
  • diagnosis of alcohol dependence according to ICD-10 (F10.2)
  • completed in-patient withdrawal treatment during the last 3 months
  • history of alcohol craving, confrmed via craving questionnaires
  • able to provide written informed consent

排除标准

  • substance dependence other than alcohol and nicotine
  • current alcohol intoxication (randomly tested via measurement of breath alcohol concentration)
  • unable to understand the study information, consent form or principles of the study
  • abstinence for less than 7 days or on-going consumption of alcohol
  • severe neuropsychiatric disorder, e.g., schizophrenia spectrum disorders, bipolar afective disorder or substantial cognitive impairment
  • somatic diseases for which VR is associated with risks, e.g. photosensitive epilepsy
  • acute suicidality or acute endangerment of others
  • concurrent pharmacological treatment targeting AUD (i.e. benzodiazepines) or craving (i.e. acamprosate, disulfram, naltrexone, nalmefene)

结局指标

主要结局

Craving

时间窗: VR-group: 6 appointments/6 weeks. Every appointment pre VR exposure / control group: 6 appointments/6 weeks, measures once every appointment, both groups: follow up appointments after 6 weeks + after 12 weeks

subjective craving for alcohol, measured with Obsessive Compulsive Drinking Scale (OCDS, scores 0-56; higher scores indicating higher craving levels)

次要结局

  • Quality of Life(both groups: assessment during appointment 1 and 6 and during follow up appointments after 6 and 12 weeks)
  • Motion Sickness(VR group: pre and post VR exposure (6 appointments/6 weeks))
  • Presence in VR(VR group: post VR exposure (6 appointments/6 weeks))
  • Relapse rates(both groups: follow up appointment after 6 weeks, follow up appointment after 12 weeks)

研究点 (1)

Loading locations...

相似试验